跳转至内容
Merck
所有图片(1)

Key Documents

View All Documentation

171610

Sigma-Aldrich

抗淀粉样蛋白前体蛋白，C-末端（751-770）兔pAb

liquid, Calbiochem®

别名:

Anti-0443, Anti-APP-CT20

登录查看公司和协议定价
所有图片(1)

About This Item

分類程式碼代碼:
12352203
NACRES:
NA.43

生物源

rabbit

品質等級

100

抗體表格

serum

抗體產品種類

primary antibodies

無性繁殖

polyclonal

形狀

liquid

物種活性

human

製造商／商標名

Calbiochem®

儲存條件

OK to freeze

同型

IgG

運輸包裝

ambient

儲存溫度

−20°C

目標翻譯後修改

unmodified

一般說明

兔多克隆抗体以未稀释的血清形式提供。识别全长APP和C端可溶性产物CTFγ（~6 kDa）、CTFα（~9 kDa）和CTFβ（~11 kDa）。
兔多克隆抗淀粉样蛋白前体蛋白C末端（751-770）可识别全长APP和C末端可溶性产物CTFα，β和γ。经验证可用于WB、IF、IHC和IP。
识别全长APP和C端可溶性产物CTFγ（~6 kDa）、CTFα（~9 kDa）和CTFβ（~11 kDa）。
  • 抗体靶基因符号：APP
  • 靶标异名：AAA，AD1，Adap，AL024401，淀粉样蛋白前体，淀粉样蛋白糖蛋白，APP异构体1，APPI，appican，CTFgamma，CVAP，E030013M08RIK，Nexin II，P3，PN2，PreA4，蛋白酶 NEXIN2
  • Entrez基因名称：淀粉样β（A4）前体蛋白
  • Hu Entrez ID：351（相关抗体：PC729, PC152,PC151, PC150, PC149, NE1012,171609, 171608, 171607, 171606, 171605, 171604, 171603, 171598, 171537)
  • Mu Entrez ID: 11820
  • 大鼠Entrez ID：54226

    • 免疫原

    人
    合成肽[(C)KMQQNGYENPTYKFFEQMQN]，对应于人前体蛋白（APP）的751-770位氨基酸，与KLH偶联

    應用

    免疫印迹（1:5000-1:20,000）

    免疫荧光（1:1000）

    免疫组织化学（1:1000）

    免疫沉淀（1:1000）

    警告

    毒性：标准处理（A）

    重構

    初次融化后，等分并冷冻（-20°C）。

    其他說明

    Pinnix, I., et al. 2001.J. Biol. Chem.276, 481.
    合适的工作稀释度由与测定条件相关的变量决定。

    法律資訊

    采购本材料仅供研究使用。在将0433抗体或任何衍生物用于临床诊断或治疗目的之前，请用户向Mayo索取许可证。有关许可信息，请联系：Mayo Medical Ventures，技术商业化办公室（507）284-8878，200 First Street SW，Rochester，MN 55905-001。
    CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

    未找到合适的产品？  

    试试我们的产品选型工具.

    儲存類別代碼

    10 - Combustible liquids

    水污染物質分類（WGK）

    WGK 1

    閃點（°F）

    Not applicable

    閃點（°C）

    Not applicable

    分析证书(COA)

    输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

    已有该产品？

    在文件库中查找您最近购买产品的文档。

    访问文档库

    Dario Tejera et al.
    The EMBO journal, 38(17), e101064-e101064 (2019-07-31)
    Alzheimer's disease is the most prevalent type of dementia and is caused by the deposition of extracellular amyloid-beta and abnormal tau phosphorylation. Neuroinflammation has emerged as an additional pathological component. Microglia, representing the brain's major innate immune cells, play an
    Inderjeet Saluja et al.
    Neurobiology of disease, 36(1), 162-168 (2009-07-28)
    The neuronal adaptor protein X11alpha/mint-1/APBA-1 binds to the cytoplasmic domain of the amyloid precursor protein (APP) to modulate its trafficking and metabolism. We investigated the consequences of reducing X11alpha in a mouse model of Alzheimer's disease (AD). We crossed hAPPswe/PS-1DeltaE9
    Ramon Velazquez et al.
    Molecular psychiatry, 25(10), 2620-2629 (2019-01-10)
    The lack of effective treatments for Alzheimer's disease (AD) is alarming, considering the number of people currently affected by this disorder and the projected increase over the next few decades. Elevated homocysteine (Hcy) levels double the risk of developing AD.
    Ramon Velazquez et al.
    Aging cell, 18(6), e13037-e13037 (2019-09-29)
    Currently, there are no effective therapies to ameliorate the pathological progression of Alzheimer's disease (AD). Evidence suggests that environmental factors may contribute to AD. Notably, dietary nutrients are suggested to play a key role in mediating mechanisms associated with brain
    Xiqian Lan et al.
    Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 7(2), 412-423 (2011-08-10)
    Combined antiretroviral therapy (ART) tremendously improved the lifespan and symptoms associated with AIDS-defining illness in affected individuals. However, chronic ART-treated patients frequently develop age-dependent complications, including dementia, diabetes, and hyperlipidemia: all risk factors of Alzheimer's disease. Importantly, the effect of
    查看所有相关文献

    我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

    联系技术服务部门